Subject(s)
Dermatology , Skin Diseases , Humans , Inpatients , Referral and Consultation , Skin Diseases/diagnosis , Skin Diseases/therapy , Perception , Retrospective StudiesABSTRACT
Cutaneous diseases of the ear encompass a wide range of symptoms, complaints, and factors that negatively impact patients' well-being. These observations are frequently encountered by otolaryngologists and other physicians who treat individuals with ear-related issues. In this document, we aim to offer up-to-date information on diagnosing, predicting outcomes, and treating commonly occurring ear diseases.
Subject(s)
Ear Diseases , Ear, External , Humans , Ear Diseases/diagnosis , Ear Diseases/therapySubject(s)
Biopsy/statistics & numerical data , Inpatients/statistics & numerical data , Referral and Consultation/trends , Skin/pathology , Telemedicine/instrumentation , Biopsy/methods , COVID-19/diagnosis , COVID-19/epidemiology , COVID-19/pathology , COVID-19/virology , Curriculum/trends , Dermatology/education , Dermatology/methods , Diagnosis, Differential , Female , Humans , Internship and Residency/statistics & numerical data , Male , Pathology/education , Pathology/methods , Quality Improvement , Retrospective Studies , SARS-CoV-2/genetics , Surveys and Questionnaires , User-Computer InterfaceABSTRACT
Antimelanoma differentiation-associated gene 5 dermatomyositis (anti-MDA5 DM) is an amyopathic subtype of DM that presents with the classic cutaneous findings of DM, such as a heliotrope rash, Gottron papules, and the shawl sign, combined with mucocutaneous ulcerations. This subtype of DM also is highly associated with rapidly progressive interstitial lung disease (ILD). We report 2 cases of a heretofore novel presentation of the overlap of these cutaneous features in the form of an ulcerative heliotrope rash; furthermore, the rash was associated with progression of ILD in both cases. Finally, we review the current state of clinical care and research related to anti-MDA5 DM in terms of clinical presentations, diagnostic methods, and treatment options.
